Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response - PubMed (original) (raw)
. 2010 Oct;17(10):1206-13.
doi: 10.1038/gt.2010.91. Epub 2010 Jun 17.
Affiliations
- PMID: 20555360
- DOI: 10.1038/gt.2010.91
Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response
A Hombach et al. Gene Ther. 2010 Oct.
Abstract
Chimeric antigen receptors (CARs, immunoreceptors) are frequently used to redirect T cells with pre-defined specificity, in particular towards tumour cells for use in adoptive immunotherapy of malignant diseases. Specific targeting is mediated by an extracellularly located antibody-derived binding domain, which is joined to the transmembrane and intracellular CD3ζ moiety for T-cell activation. Stable CAR expression in T cells, however, requires a spacer domain interposed between the binding and the transmembrane domain and which is commonly the constant IgG1 Fc domain. We here revealed that CARs with Fc spacer domain bind to IgG Fc gamma receptors (FcγRs), thereby unintentionally activating innate immune cells, including monocytes and natural killer (NK) cells, which consequently secrete high amounts of pro-inflammatory cytokines. Engineered T cells, on the other hand, are likewise activated by FcγR binding resulting in cytokine secretion and lysis of monocytes and NK cells independently of the redirected specificity. To reduce FcγR binding, we modified the spacer domain without affecting CAR expression and antigen binding. Engineered with the modified CAR, T cells are not activated in presence of FcγR(+) cells, thereby minimizing the risk of off-target activation while preserving their redirected targeting specificity.
Comment in
- Carving the CAR.
Riddell SR, Protzer U. Riddell SR, et al. Gene Ther. 2010 Oct;17(10):1191-2. doi: 10.1038/gt.2010.96. Epub 2010 Jul 29. Gene Ther. 2010. PMID: 20668483 Free PMC article. No abstract available.
Similar articles
- Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.
Sharifzadeh Z, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Jamnani FR, Moghimi SM. Sharifzadeh Z, et al. Cancer Lett. 2013 Jul 1;334(2):237-44. doi: 10.1016/j.canlet.2012.08.010. Epub 2012 Aug 16. Cancer Lett. 2013. PMID: 22902507 - The T-body approach: redirecting T cells with antibody specificity.
Eshhar Z. Eshhar Z. Handb Exp Pharmacol. 2008;(181):329-42. doi: 10.1007/978-3-540-73259-4_14. Handb Exp Pharmacol. 2008. PMID: 18071952 Review. - T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition.
Hombach A, Heuser C, Gerken M, Fischer B, Lewalter K, Diehl V, Pohl C, Abken H. Hombach A, et al. Gene Ther. 2000 Jun;7(12):1067-75. doi: 10.1038/sj.gt.3301195. Gene Ther. 2000. PMID: 10871757 - Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy.
Riet T, Holzinger A, Dörrie J, Schaft N, Schuler G, Abken H. Riet T, et al. Methods Mol Biol. 2013;969:187-201. doi: 10.1007/978-1-62703-260-5_12. Methods Mol Biol. 2013. PMID: 23296935 Review.
Cited by
- High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-ζ) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy.
Gallego-Valle J, Pérez-Fernández VA, Rosales-Magallares J, Gil-Manso S, Castellá M, Gonzalez-Navarro EA, Correa-Rocha R, Juan M, Pion M. Gallego-Valle J, et al. Front Immunol. 2024 Sep 19;15:1448752. doi: 10.3389/fimmu.2024.1448752. eCollection 2024. Front Immunol. 2024. PMID: 39364400 Free PMC article. - Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma.
Ren T, Huang Y. Ren T, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep 24. doi: 10.1007/s00210-024-03443-7. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 39316087 Review. - Novel modular chimeric antigen receptor spacer for T cells derived from signal regulatory protein alpha Ig-like domains.
Koski J, Jahan F, Luostarinen A, Schenkwein D, Ylä-Herttuala S, Göös H, Monzo H, Ojala PM, Maliniemi P, Korhonen M. Koski J, et al. Front Mol Med. 2022 Dec 13;2:1049580. doi: 10.3389/fmmed.2022.1049580. eCollection 2022. Front Mol Med. 2022. PMID: 39086976 Free PMC article. - Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors.
Jahan F, Koski J, Schenkwein D, Ylä-Herttuala S, Göös H, Huuskonen S, Varjosalo M, Maliniemi P, Leitner J, Steinberger P, Bühring HJ, Vettenranta K, Korhonen M. Jahan F, et al. Front Mol Med. 2023 Feb 22;3:1070384. doi: 10.3389/fmmed.2023.1070384. eCollection 2023. Front Mol Med. 2023. PMID: 39086686 Free PMC article. - Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.
Cortese M, Torchiaro E, D'Andrea A, Petti C, Invrea F, Franco L, Donini C, Leuci V, Leto SM, Vurchio V, Cottino F, Isella C, Arena S, Vigna E, Bertotti A, Trusolino L, Sangiolo D, Medico E. Cortese M, et al. Mol Ther. 2024 Aug 7;32(8):2741-2761. doi: 10.1016/j.ymthe.2024.06.023. Epub 2024 Jun 17. Mol Ther. 2024. PMID: 38894542 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources